Peptides
CJC-1295 without DAC (Modified GRF 1-29)
Also called Mod GRF 1-29 · CJC-1295 NO DAC · CJC no DAC
People explore CJC-1295 without DAC for better sleep, workout recovery and changes in muscle or body fat, often alongside ipamorelin. Reported routines involve frequent injections; reliable enhancement benefits remain uncertain.
Dosage & duration
CXPeptides’ published no-DAC examples, injected under the skin. Supplier suggestions, not clinical-trial regimens.
CXPeptides: sleep/recovery example
Published example · product-specific- Dose
- 100 mcg per administration
- How often
- Once daily
- How long
- 8 weeks
The sheet labels this as a sleep/recovery goal; it supplies no separate starting or maintenance phase.
Sources: 2
CXPeptides: muscle-building example
Published example · product-specific- Dose
- 100–200 mcg per administration
- How often
- Once or twice daily
- How long
- 8–12 weeks
At twice daily, this means 200–400 mcg of no-DAC that day, before counting any other ingredient.
Sources: 2
These examples describe no-DAC alone, not the combined amount in a CJC/ipamorelin blend. The supplier states research-only, not therapeutic use.
More quick facts
- Why people seek it
- Sleep, recovery and physique
- Bedtime question
- Better sleep is not guaranteed
The practical difference
No DAC or DAC: check the form
Check the form before comparing routines.
| What changes | No DAC / modified GRF | CJC-1295 with DAC |
|---|---|---|
| Reported routine | Daily supplier examples | Human trial: weekly or every two weeks |
| DAC attachment | No albumin-binding attachment | Binds to a blood protein |
| GH-pulse question | No proven sleep or recovery advantage | Pulses persisted in the human study |
What it is
CJC-1295 no DAC attracts people hoping to sleep more deeply, feel ready for the next workout and improve their physique without taking growth hormone itself. It is intended to signal the pituitary to release GH. That explains the interest; it does not supply a dependable estimate of extra muscle, fat loss or faster injury healing.
The discussions reviewed include perceived improvements, little noticeable change and unwanted effects. Several users were also changing training, diet or other drugs. Treat those experiences as reports, not a timetable for what should happen to you.
Timing in the body
“No DAC” usually refers to modified GRF(1–29). It lacks the attachment used to make the studied DAC form remain in circulation longer. For the reader, the important trade-off is the repeated daily routine described for no DAC versus the longer-lasting DAC form.
The often-quoted 30-minute no-DAC half-life is not a well-established human measurement in the sources checked. The plotter’s short curve uses relative units and assumed timing; it does not show a measured peptide level, GH pulse or tonight’s sleep. The separate DAC study found that GH pulses persisted, so “no DAC preserves pulses and DAC removes them” is not an accurate comparison.
What matters in a blend?
Ipamorelin pairing is discussed because it and a GHRH analogue use different GH-related signaling routes. A plausible reason to combine them does not establish that the combination improves sleep or body composition more than either alone. It also does not show that ipamorelin is required for no DAC to have biological activity.
Read the amounts separately. “100 mcg CJC no DAC + 100 mcg ipamorelin” means 200 mcg combined, not 200 mcg of each. A vial described as 5 mg + 5 mg likewise contains 10 mg total. The name should specify no DAC, each component’s amount and the final concentration; a shared vial is not evidence of mixing stability.
What do the reported courses tell you?
The visible examples keep dose, frequency and duration together from one explicitly no-DAC supplier sheet. Their eight- to twelve-week windows are suggested courses, not evidence of when benefits begin or a proven safe cycle. Other clinic and community sources describe different routines.
Bedtime and five-days-on/two-days-off patterns also appear in discussions. The evidence checked does not establish that a particular clock time improves sleep, or that days off reset receptors or remove long-term risk. Compare per-administration amounts and daily totals before comparing two reports.
Benefits and downsides to judge separately
For a sleep goal, look at sleep quality and next-day function. For recovery, consider whether normal training is becoming easier to tolerate. A higher GH or IGF-1 blood result alone does not demonstrate either benefit, and a changing scale weight cannot distinguish muscle gain from fluid changes.
FDA’s review raises GH/IGF-1-related concerns such as fluid retention and impaired glucose handling, alongside peptide-product quality and immune-response concerns. It does not establish how often those problems occur with no DAC. Repeated injections and additional ingredients bring practical burdens too; adding a second peptide makes it harder to identify the cause of a benefit or a reaction. Persistent poor sleep, swelling, numbness or palpitations deserves clinical assessment rather than automatic dose escalation.
Model details: CJC-1295 without DAC (Modified GRF 1-29) · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Retained historical illustrative timing assumption only; no validated human SC half-life recovered for this specific form.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 0.48 hours
- Absorption half-life assumed
- 0.12 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (0.12 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Identity/salt ambiguity persists; no-DAC is not the DAC molecule with a different schedule.
- No measured SC F,Tmax or concentration amplitude supports the current curve.
- Relative output must explicitly identify timing assumption.
- FDA CJC-1295 scientific review
Human studies reviewed used DAC active moiety; FDA did not identify human PK for the other nominated forms and records naming/identity ambiguity.
cjc-1295-no-dac-relative-timing-2026-10 · version 1
Common questions
Why do people pair no-DAC CJC with ipamorelin?
They are discussed as complementary GH-related signals. That rationale does not prove better sleep, recovery or muscle gain from the combination, and a blend needs its own ingredient amounts and product documentation.
Does 100/100 mean a 100 mcg total blend dose?
If it means 100 mcg of CJC no DAC plus 100 mcg of ipamorelin, the combined amount is 200 mcg. Abbreviated posts can be ambiguous, so confirm which number refers to each ingredient and which refers to the total.
Is an eight- or twelve-week course a proven safe cycle?
No. The durations shown are the named supplier’s published examples. They do not establish a benefit timeline, safety limit or evidence-based break schedule.
Can I use the weekly CJC-1295 study schedule for no DAC?
That study used the long-acting DAC form. Its schedule and dose cannot be transferred to modified GRF(1–29) just because both names include CJC-1295.
Does a 30-minute half-life mean the sleep effect lasts 30 minutes?
No. The human no-DAC half-life itself is not well established in the sources checked, and peptide clearance is different from the duration of a downstream hormone response or a change in sleep.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Why people seek it
- These are the goals discussed by users, rather than predictable results for everyone.
- Bedtime question
- Readers report both favorable and unfavorable sleep experiences with CJC/ipamorelin combinations.
- Pairing with ipamorelin
- A blend’s total micrograms and the amount of each ingredient are different numbers.
- 1. FDA — CJC-1295 scientific review, December 2024
Full briefing checked: pages 7–9 distinguish DAC and no-DAC active molecules; pages 24–27 describe marketing and blends; pages 41–45 discuss GH-related concerns and the lack of direct no-DAC clinical safety data. The nominated GH-deficiency review is not an enhancement trial or a current compounding-status determination.
- 2. CXPeptides — published CJC-no-DAC product-sheet examples
Two-page supplier PDF opened 7 Oct 2026. Page 1 specifies CJC-no-DAC and the subcutaneous route; page 2 lists sleep/recovery at 100 mcg once daily for 8 weeks and muscle building at 100–200 mcg per administration 1–2 times daily for 8–12 weeks. The same sheet says research-only/not approved for therapeutic use. Reported examples only: benefit, safety, pen calibration, site and storage claims are not adopted.
- 3. Teichman et al. — long-acting CJC-1295 in healthy adults
The 2006 placebo-controlled studies measured exposure and GH/IGF-1 responses to the albumin-binding DAC form. They do not establish no-DAC doses, sleep improvement, muscle gain or a blend regimen.
- 4. Ionescu and Frohman — GH pulses during CJC-1295 exposure
Healthy men receiving the long-acting DAC molecule retained pulsatile GH secretion. This contradicts the claim that DAC necessarily eliminates pulses; it does not establish no-DAC superiority.
- 5. FDA CJC-1295 scientific review
Human studies reviewed used DAC active moiety; FDA did not identify human PK for the other nominated forms and records naming/identity ambiguity.
- 6. Raun et al. — ipamorelin receptor pharmacology
Original 1998 cell/rat/swine work: antagonist profiling distinguishes ipamorelin’s GHRP-like receptor action from GHRH signaling. Used only for the pairing rationale, not proof of a no-DAC/ipamorelin benefit or a required combination in people.
Keep reading
Related compounds and examples
Related compounds
CJC-1295 with DAC
CJC-1295 with DAC appeals to people seeking longer-lasting GH stimulation with fewer injections. Compare reported weekly use, trial doses, recovery goals and the trade-offs.
Sermorelin
Sermorelin for sleep and recovery: reported clinic doses, treatment time and differences from HGH.
Tesamorelin
Tesamorelin for visceral belly fat: Egrifta doses, how long treatment is studied and what happens after stopping.